Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-114811 · Präparat HOS-094169
Abacavir 300 mg BID Abacavir Cmax ↓ 46% The concomitant use of Aptivus, (TPV/r 750/100 mg BID) Abacavir AUC ↓ 36% co-administered with low dose ritonavir, with abacavir is not The clinical relevance of this recommended unless there are no reduction has not been other available NRTIs suitable for established, but may decrease patient management. In such the efficacy of abacavir. cases no dosage adjustment of abacavir can be recommended Mechanism unknown. (see section 4.4). Didanosine 200 mg BID, Didanosine Cmax ↓ 43% Dosing of enteric-coated ≥ 60 kg (TPV/r 250/200 mg Didanosine AUC ↓ 33% didanosine and Aptivus soft BID) - 125 mg BID, < 60 kg capsules, co-administered with (TPV/r 750/100 mg BID) low dose ritonavir, should be Didanosine Cmax ↓ 24% separated by at least 2 hours to Didanosine AUC ↔ avoid formulation incompatibility. The clinical relevance of this reduction in didanosine concentrations has not been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) ritonavir (HOS-084521) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage dc467715c0253d376232fd8621af28714f574b47724b843a086e90ab970bca73 · Zeichen 4554–6273 im Abschnitt